AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 88 (Currently amended): An antigenic composition consisting of an antigen and an effective adjuvanting amount of the combination of: (1) 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A, and (2) ~~a cytokine or lymphokine selected from the group consisting of~~ granulocyte macrophage colony stimulating factor (GM-CSF) ~~and interleukin-12 (IL-12)~~, together with a diluent or carrier.

Claim 89 (Previously presented): The antigenic composition of claim 88, where the antigen is a polypeptide, peptide or fragment derived from a protein.

Claim 90 (Previously presented): The antigenic composition of claim 88, where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

Claims 91-97 (Canceled)

Claim 98 (Previously presented): The antigenic composition of claim 88, where the antigen is derived from a pathogenic virus.

Claim 99-104 (Withdrawn)

Claim 105 (Previously presented): A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic virus to elicit an immune response in a vertebrate host against said pathogenic virus, which comprises administering to said host an antigenic composition of claim 98.

Claim 106-108 (Withdrawn)

Claim 109 (Previously presented): A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic virus to elicit cytotoxic T lymphocytes responses in a vertebrate host, which comprises administering to said host an antigenic composition of claim 98.

Claim 110-115 (Withdrawn)

Claim 116 (Previously presented): The antigenic composition of claim 98, where the antigen is from human immunodeficiency virus (HIV).

Claim 117 (Previously presented): The antigenic composition of claim 116, where the HIV antigen is an HIV protein, polypeptide, peptide or fragment derived from said protein.

Claim 118 (Previously presented): The antigenic composition of Claim 117 where the antigen is the HIV peptide having the amino acid sequence:
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:1), or
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

Claim 119 (Original): The antigenic composition of claim 116, where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

Claims 120-126 (Canceled)

Claim 127-130 (Withdrawn)

Claims 131-137 (Canceled)

Claim 138-141 (Withdrawn)

Claims 142-148 (Canceled)

Claim 149-152 (Withdrawn)

Claims 153-159 (Canceled)

Claim 160 (Previously presented): A method for increasing the ability of an antigenic composition containing an HIV antigen to elicit an immune response to said antigen in a vertebrate host, which comprises administering to said host an antigenic composition of claim 116.

Claim 161 (Canceled)

Claim 162 (Withdrawn)

Claim 163 (Previously presented): The method of claim 160, where the HIV antigen is the HIV peptide having the amino acid sequence:
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

Claim 164 (Previously presented): A method for increasing the ability of an antigenic composition containing an HIV antigen to elicit cytotoxic T lymphocyte responses in a vertebrate host, which comprises administering to said host an antigenic composition of claim 116.

Claim 165 (Canceled)

Claim 166 (Withdrawn)

Claim 167 (Previously presented): The method of claim 164, where the HIV antigen is the HIV peptide having the amino acid sequence:
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

Claim 168 (Withdrawn)

Claim 169 (Canceled)

Claim 170-171 (Withdrawn)

Claim 172 (Canceled)

Claim 173-174 (Withdrawn)

Claim 175 (Canceled)

Claim 176-177 (Withdrawn)

Claim 178 (Canceled)

Claim 179-180 (Withdrawn)

Claim 181 (Canceled)

Claim 182-183 (Withdrawn)

Claim 184 (Canceled)

Claim 185 (Withdrawn)

Claim 186 (New): An antigenic composition consisting of an antigen and an effective adjuvanting amount of the combination of: (1) 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A, and (2) ~~a cytokine or lymphokine selected from the group consisting of granulocyte macrophage colony stimulating factor (GM-CSF) and~~ interleukin-12 (IL-12), together with a diluent or carrier.

Claim 187 (New): The antigenic composition of claim 186, where the antigen is a polypeptide, peptide or fragment derived from a protein.

Claim 188 (New): The antigenic composition of claim 186, where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

Claim 189 (New): The antigenic composition of claim 186, where the antigen is derived from a pathogenic virus.

Claim 190 (New): A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic virus to elicit an immune response in a vertebrate host against said pathogenic virus, which comprises administering to said host an antigenic composition of claim 189.

Claim 191 (New): A method for increasing the ability of an antigenic composition containing an antigen from a pathogenic virus to elicit cytotoxic T lymphocyte~~s~~ responses in a vertebrate host, which comprises administering to said host an antigenic composition of claim 189.

Claim 192 (New): The antigenic composition of claim 189, where the antigen is from human immunodeficiency virus (HIV).

Claim 193 (New): The antigenic composition of claim 192, where the HIV antigen is an HIV protein, polypeptide, peptide or fragment derived from said protein.

Claim 194 (New): The antigenic composition of Claim 193 where the antigen is the HIV peptide having the amino acid sequence:
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:1), or
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

Claim 195 (New): The antigenic composition of claim 192, where 3-O-deacylated monophosphoryl lipid A is used in the form of a stable oil-in-water emulsion.

Claim 196 (New): A method for increasing the ability of an antigenic composition containing an HIV antigen to elicit an immune response to said antigen in a vertebrate host, which comprises administering to said host an antigenic composition of claim 192.

Claim 197 (New): The method of claim 196, where the HIV antigen is the HIV peptide having the amino acid sequence:
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).

Claim 198 (New): A method for increasing the ability of an antigenic composition containing an HIV antigen to elicit cytotoxic T lymphocyte responses in a vertebrate host, which comprises administering to said host an antigenic composition of claim 192.

Claim 199 (New): The method of claim 198, where the HIV antigen is the HIV peptide having the amino acid sequence:
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys (SEQ ID NO:2).